USCOM LIMITED — Capital/Financing Update 2011

Jan 13, 2011

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

Expected differences in financial results

Friday 14th of January, 2011: Uscom (ASX code: UCM).

Under listing rule 3.1 in relation to any expected material variations in their financial results (variance of 15% or greater), Uscom Limited today announced that it expected its results for the period ending 31 December 2010 to be lower than the corresponding period ending 31 December 2009, primarily due to the effect of the strong Australian dollar.

The net loss for the period ending 31 December 2010, before the foreign exchange impact, is expected to be $78k lower than the previous corresponding period ending 31 December 2009. This represents a 9% increase in the loss which is well below the material difference guideline of 15%.

Including the impact of the high Australia dollar on the results for the period ending 31 December 2010, the net loss for the period ending 31 December 2010 is expected to be $1,050m ($830k 31 December 2009). This represents a $218k variance which is a 26% change from the corresponding period. The impact from the foreign exchange calculation is $140k which is a significant portion of the variance.

Uscom also announces separately today, the signing of a 2[nd] Distribution partner in the US market and that the company is progressing its plans to create a global distribution channel for Uscom.

Uscom also recently announced that it had reconstituted its board with the appointment of Phil Kiely as Executive Chairman and Yochen Bonitz as a new Director. Uscom has also successfully completed a private placement for $3million which was fully allocated and has embarked on an ambitious plan to create a new global distribution channel and re energise its sales and marketing focus.

About Uscom

Uscom Limited is an Australian medical device company which was first listed on the Australian Stock Exchange in December 2003. Uscom has developed a Non Invasive Cardiac Output Monitor. The USCOM is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency Medicine, Intensive Care Units and Anesthesia, and is a tool of choice for management of adult and paediatric sepsis, and for the guidance of all fluid administration. USCOM has global regulatory approval and the technology is currently marketed in North America, South America, Europe, the Middle East, India, Australia & New Zealand. China and SE Asia.

Uscom Contacts Phil Kiely Executive Chairman phil.kiely@uscom.com.au

Daniel Fah Company Secretary daniel.fah@uscom.com.au